Literature DB >> 19563267

The search for new COX-2 inhibitors: a review of 2002 - 2008 patents.

Teodorico C Ramalho1, Marcus V J Rocha, Elaine F F da Cunha, Matheus P Freitas.   

Abstract

BACKGROUND: Two COX isoenzymes are known, COX-1 and COX-2, for which the main inhibitors are the NSAIDs. The common anti-inflammatory drugs (such as aspirin, ibuprofen and naproxen) all act by blocking the action of both the COX-1 and COX-2 enzymes. The COX-2 inhibitors represent a new class of drugs that do not affect COX-1 but selectively block COX-2. This selective action provides the benefits of reducing inflammation without irritating the stomach and cardiovascular effects.
OBJECTIVE: This review focuses on patents published in the field during 2002 - 2008, paying particular attention to promising COX-2 inhibitors.
CONCLUSION: Structural analogues of the COX-2 inhibitors celecoxib and valdecoxib, and novel potential pyridazine, triazole, indole and thione derivatives emerge as promising leads for the treatment of inflammation, pain and other diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563267     DOI: 10.1517/13543770903059125

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  9 in total

Review 1.  Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.

Authors:  Hayamitsu Adachi; Koichi Nakae; Shuichi Sakamoto; Chisato Nosaka; Sonoko Atsumi; Masabumi Shibuya; Nobuaki Higashi; Motowo Nakajima; Tatsuro Irimura; Yoshio Nishimura
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

Review 2.  Targeting AMPK for the Alleviation of Pathological Pain.

Authors:  Marina N Asiedu; Gregory Dussor; Theodore J Price
Journal:  Exp Suppl       Date:  2016

3.  Rapid changes in histone deacetylases and inflammatory gene expression in expert meditators.

Authors:  Perla Kaliman; María Jesús Alvarez-López; Marta Cosín-Tomás; Melissa A Rosenkranz; Antoine Lutz; Richard J Davidson
Journal:  Psychoneuroendocrinology       Date:  2013-11-15       Impact factor: 4.905

4.  2-Carbaborane-3-phenyl-1H-indoles--synthesis via McMurry reaction and cyclooxygenase (COX) inhibition activity.

Authors:  Markus Laube; Wilma Neumann; Matthias Scholz; Peter Lönnecke; Brenda Crews; Lawrence J Marnett; Jens Pietzsch; Torsten Kniess; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2013-01-09       Impact factor: 3.466

Review 5.  Could Quantum Mechanical Properties Be Reflected on Classical Molecular Dynamics? The Case of Halogenated Organic Compounds of Biological Interest.

Authors:  Lucas de Azevedo Santos; Ingrid G Prandi; Teodorico C Ramalho
Journal:  Front Chem       Date:  2019-12-13       Impact factor: 5.221

Review 6.  Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years.

Authors:  Zhiran Ju; Menglan Li; Junde Xu; Daniel C Howell; Zhiyun Li; Fen-Er Chen
Journal:  Acta Pharm Sin B       Date:  2022-01-11       Impact factor: 14.903

7.  Structural and Energetic Properties of Weak Noncovalent Interactions in Two Closely Related 3,6-Disubstituted-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole Derivatives: In Vitro Cyclooxygenase Activity, Crystallography, and Computational Investigations.

Authors:  Lamya H Al-Wahaibi; Sekar Karthikeyan; Olivier Blacque; Amal A El-Masry; Hanan M Hassan; M Judith Percino; Ali A El-Emam; Subbiah Thamotharan
Journal:  ACS Omega       Date:  2022-09-16

Review 8.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Progress in Small Molecule Drug Development.

Authors:  Praveen P N Rao; Saad N Kabir; Tarek Mohamed
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-14

Review 9.  Vitamin D in inflammatory diseases.

Authors:  Thea K Wöbke; Bernd L Sorg; Dieter Steinhilber
Journal:  Front Physiol       Date:  2014-07-02       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.